A carregar...
Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials
BACKGROUND AND AIMS: In the 4-week GAIN clinical trial, adalimumab was efficacious in inducing remission in patients with moderate-to-severe Crohn’s disease [CD] who had prior loss of response/intolerance to infliximab. The efficacy and safety of adalimumab in these patients are reported here for up...
Na minha lista:
| Publicado no: | J Crohns Colitis |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6065484/ https://ncbi.nlm.nih.gov/pubmed/29697818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjy050 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|